How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example

References

• Mahfoud F, Lüscher TF, Andersson B, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149–2157.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–1357.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Redon J, Grassi G, et al. ESH position paper: renal denervation: an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837–841.
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–1281.
   PubMed Web of Science ®Google Scholar
• Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–1909.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–1401.
   PubMed Web of Science ®Google Scholar
• Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet Lond Engl. 2015;385:1957–1965.
   PubMed Web of Science ®Google Scholar
• Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertens (Dallas Tex 1979). 2015;65:407–413.
   PubMed Web of Science ®Google Scholar
• Fadl Elmula FEM, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertens (1979). 2014;63:991–999.
   PubMed Web of Science ®Google Scholar
• Desch S, Okon T, Heinemann D, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertens (1979). 2015;65:1202–1208.
   PubMed Web of Science ®Google Scholar
• Kario K, Ogawa H, Okumura K, et al. SYMPLICITY HTN-Japan: first randomized controlled trial of catheter-based renal denervation in asian patients. Circ J. 2015;79:1222–1229.
   PubMed Web of Science ®Google Scholar
• Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016;34:1639–1647.
   PubMed Web of Science ®Google Scholar
• Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study: a randomized controlled trial. J Hypertens. 2016;34:1863–1871.
   PubMed Web of Science ®Google Scholar
• de Jager RL, de Beus E, Beeftink MMA, et al. Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertens (1979). 2017;69:678–684.
   PubMed Web of Science ®Google Scholar
• Townsend RR, Mahfoud F, Kandzari DE, etet al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet Lond Engl. 2017;Aug 25. [Epub ahead of print].
   Google Scholar
• Fadl Elmula FEM, Feng Y-M, Jacobs L, et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Press. 2017;26:195–203.
   PubMed Web of Science ®Google Scholar
• Henry TL, De Brouwer BFE, Van Keep MML, et al. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands. J Med Econ. 2015;18:76–87.
   PubMed Web of Science ®Google Scholar
• Tilden D, McBride M, Whitbourn R, et al. Cost effectiveness of catheter-based renal denervation for treatment resistant hypertension: an Australian payer perspective. Value Health. 2014;17:A762.
   PubMed Web of Science ®Google Scholar
• Gladwell D, Henry T, Cook M, et al. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. Appl Health Econ Health Policy. 2014;12:611–622.
   PubMedGoogle Scholar
• Kontsevaia AV, Suvorova EI, Khudiakov MB. [Economic efficiency of renal denervation in patients with resistant hypertension: results of Markov modeling]. Kardiologiia. 2014;54:41–47.
   PubMed Web of Science ®Google Scholar
• Dorenkamp M, Bonaventura K, Leber AW, et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J. 2013;34:451–461.
   PubMed Web of Science ®Google Scholar
• Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60:1271–1277.
   PubMed Web of Science ®Google Scholar
• Raftery J, Young A, Stanton L, et al. Theme 5: economic analysis alongside clinical trials [Internet]. NIHR Journals Library; 2015 [cited 2017 May 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK274338/
   Google Scholar
• Guide méthodologique pour l’évaluation économique des stratégies de santé [Internet]. Collège Économistes Santé. 2013 [cited 2017 May 19]. Available from: http://www.ces-asso.org/sites/default/files/Guide_Methodologique_CES_2003.pdf
   Google Scholar
• Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005;187:106–108.
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6:217–227.
   PubMed Web of Science ®Google Scholar
• Pratley RE. The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare? Diabetologia. 2014;57:1273–1275.
   PubMedGoogle Scholar
• Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics. 1999;15:423–434.
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.
   PubMed Web of Science ®Google Scholar
• D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753.
   PubMed Web of Science ®Google Scholar
• JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart Br Card Soc. 2014;100(Suppl 2):ii1–ii67.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–250.
   PubMed Web of Science ®Google Scholar
• Haute Autorité de Santé. Guide méthodologique: Choix méthodologiques pour l’évaluation économique à la HAS. [Internet]. 2011. Available from: https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf
   Google Scholar
• Grossman E. Blood Pressure: the lower, the better. Diabetes Care. 2011;34:S308–S312.
   PubMed Web of Science ®Google Scholar
• Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967.
   PubMed Web of Science ®Google Scholar